NO309798B1 - Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen - Google Patents
Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen Download PDFInfo
- Publication number
- NO309798B1 NO309798B1 NO19992102A NO992102A NO309798B1 NO 309798 B1 NO309798 B1 NO 309798B1 NO 19992102 A NO19992102 A NO 19992102A NO 992102 A NO992102 A NO 992102A NO 309798 B1 NO309798 B1 NO 309798B1
- Authority
- NO
- Norway
- Prior art keywords
- peptides
- peptide
- patients
- ras
- cells
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 107
- 239000000203 mixture Substances 0.000 title claims description 30
- 238000009566 cancer vaccine Methods 0.000 title claims description 5
- 229940022399 cancer vaccine Drugs 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 108010014186 ras Proteins Proteins 0.000 claims description 62
- 102000016914 ras Proteins Human genes 0.000 claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 52
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 13
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 10
- 102000043276 Oncogene Human genes 0.000 claims description 10
- 108700020796 Oncogene Proteins 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 230000005867 T cell response Effects 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 47
- 238000002255 vaccination Methods 0.000 description 31
- 230000035772 mutation Effects 0.000 description 25
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 18
- 230000008105 immune reaction Effects 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 12
- 201000002528 pancreatic cancer Diseases 0.000 description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 230000009257 reactivity Effects 0.000 description 8
- 230000009260 cross reactivity Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 108700020978 Proto-Oncogene Proteins 0.000 description 4
- 102000052575 Proto-Oncogene Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 101150080340 tlcD gene Proteins 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- -1 Fmoc amino acids Chemical class 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 101150009136 tlcA gene Proteins 0.000 description 1
- 101150071385 tlcB gene Proteins 0.000 description 1
- 101150020044 tlcE gene Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO19992102A NO309798B1 (no) | 1999-04-30 | 1999-04-30 | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| EP00925746A EP1173199A1 (fr) | 1999-04-30 | 2000-04-28 | VACCINS A BASE DE PEPTIDES p21 RAS ONCOGENIQUE |
| PCT/NO2000/000142 WO2000066153A1 (fr) | 1999-04-30 | 2000-04-28 | VACCINS A BASE DE PEPTIDES p21 RAS ONCOGENIQUE |
| CA002372187A CA2372187A1 (fr) | 1999-04-30 | 2000-04-28 | Vaccins a base de peptides p21 ras oncogenique |
| AU44389/00A AU4438900A (en) | 1999-04-30 | 2000-04-28 | Ras oncogen p21 peptide vaccines |
| JP2000615037A JP2002543149A (ja) | 1999-04-30 | 2000-04-28 | ＲＡＳオンコージンｐ２１ペプチドワクチン |
| ARP000102059A AR023806A1 (es) | 1999-04-30 | 2000-04-28 | Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO19992102A NO309798B1 (no) | 1999-04-30 | 1999-04-30 | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO992102D0 NO992102D0 (no) | 1999-04-30 |
| NO992102L NO992102L (no) | 2000-10-31 |
| NO309798B1 true NO309798B1 (no) | 2001-04-02 |
Family
ID=19903274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19992102A NO309798B1 (no) | 1999-04-30 | 1999-04-30 | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1173199A1 (fr) |
| JP (1) | JP2002543149A (fr) |
| AR (1) | AR023806A1 (fr) |
| AU (1) | AU4438900A (fr) |
| CA (1) | CA2372187A1 (fr) |
| NO (1) | NO309798B1 (fr) |
| WO (1) | WO2000066153A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2402364A2 (fr) | 2008-11-26 | 2012-01-04 | Lytix Biopharma AS | Nonapeptide avec activité anti-tumeur |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2836684B1 (fr) * | 2002-03-04 | 2004-12-17 | Inst Nat Sante Rech Med | Peptides ras mutes et leur utilisation en immunotherapie |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| CN102370974B (zh) | 2002-12-16 | 2014-09-17 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| MX2008012392A (es) | 2006-03-27 | 2008-12-17 | Globeimmune Inc | Mutacion de ras, y composiciones y metodos relacionados con la misma. |
| NZ620441A (en) * | 2009-09-03 | 2015-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| ES2788863T3 (es) | 2010-05-14 | 2020-10-23 | Massachusetts Gen Hospital | Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores |
| CN102060929A (zh) * | 2010-06-07 | 2011-05-18 | 夏书奇 | T细胞免疫平衡肽 |
| US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| BR112016013138A2 (pt) | 2013-12-09 | 2018-01-16 | Targovax Asa | mistura de peptídeos |
| CN106456724A (zh) | 2013-12-20 | 2017-02-22 | 博德研究所 | 使用新抗原疫苗的联合疗法 |
| SG11201608712PA (en) | 2014-05-06 | 2016-11-29 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| WO2016100975A1 (fr) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Biomarqueurs moléculaires pour l'immunothérapie d'un cancer |
| TWI806815B (zh) | 2015-05-20 | 2023-07-01 | 美商博德研究所有限公司 | 共有之ｇａｔａ３相關之腫瘤特異性新抗原 |
| JP2018518177A (ja) * | 2015-06-16 | 2018-07-12 | タルゴバックス エーエスエー | Ｒａｓタンパク質の突然変異フラグメント |
| EP3574116A1 (fr) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions et procédés de détection d'un variant mutant d'un polynucléotide |
| CN110430894A (zh) | 2017-02-01 | 2019-11-08 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
| EP3576764A4 (fr) * | 2017-02-03 | 2020-12-16 | The Medical College of Wisconsin, Inc. | Compositions de vaccin peptidique kras et procédé d'utilisation |
| WO2019126186A1 (fr) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Néo-antigènes et leurs utilisations |
| CN114573688A (zh) * | 2018-10-19 | 2022-06-03 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
| JPWO2020145222A1 (fr) * | 2019-01-07 | 2020-07-16 | ||
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| CN115916234A (zh) * | 2020-02-19 | 2023-04-04 | 艾琳治疗公司 | 靶向ras蛋白的分子 |
| AU2021223703A1 (en) * | 2020-02-19 | 2022-08-25 | Aelin Therapeutics | Molecules targeting proteins |
| WO2022219152A1 (fr) * | 2021-04-16 | 2022-10-20 | Oblique Therapeutics Ab | Anticorps kras |
| WO2024112821A1 (fr) * | 2022-11-22 | 2024-05-30 | Elixirgen Therapeutics, Inc. | Antigènes pour immunothérapie anticancéreuse |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957859A (en) * | 1988-02-16 | 1990-09-18 | Hoffmann-La Roche Inc. | Antibodies for transforming ras protein |
| GB9103974D0 (en) * | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| DK0895538T3 (da) * | 1996-04-19 | 2002-11-04 | Us Gov Sec Health | Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter |
| GB9620350D0 (en) * | 1996-09-30 | 1996-11-13 | Maudsley David J | Cancer vaccine |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
-
1999
- 1999-04-30 NO NO19992102A patent/NO309798B1/no not_active IP Right Cessation
-
2000
- 2000-04-28 JP JP2000615037A patent/JP2002543149A/ja active Pending
- 2000-04-28 AR ARP000102059A patent/AR023806A1/es unknown
- 2000-04-28 AU AU44389/00A patent/AU4438900A/en not_active Abandoned
- 2000-04-28 WO PCT/NO2000/000142 patent/WO2000066153A1/fr not_active Application Discontinuation
- 2000-04-28 EP EP00925746A patent/EP1173199A1/fr not_active Withdrawn
- 2000-04-28 CA CA002372187A patent/CA2372187A1/fr not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2402364A2 (fr) | 2008-11-26 | 2012-01-04 | Lytix Biopharma AS | Nonapeptide avec activité anti-tumeur |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1173199A1 (fr) | 2002-01-23 |
| NO992102L (no) | 2000-10-31 |
| AU4438900A (en) | 2000-11-17 |
| JP2002543149A (ja) | 2002-12-17 |
| AR023806A1 (es) | 2002-09-04 |
| NO992102D0 (no) | 1999-04-30 |
| WO2000066153A1 (fr) | 2000-11-09 |
| CA2372187A1 (fr) | 2000-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO309798B1 (no) | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen | |
| US20230414735A1 (en) | Neoantigens and methods of their use | |
| EP0529023B1 (fr) | Peptides et fragments de peptides efficaces therapeutiquement | |
| JP4422903B2 (ja) | 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原 | |
| WO2004024766A1 (fr) | Peptides kdr et vaccins les renfermant | |
| TW201041593A (en) | Cancer antigen helper peptide | |
| JP4051602B2 (ja) | 腫瘍抗原 | |
| JP2001514190A (ja) | 細胞傷害性ｔ細胞免疫を引き出すペプチド | |
| AU2002304165B2 (en) | Polynucleotide vaccine | |
| RU2773273C2 (ru) | Неоантигены и способы их использования | |
| AU2021226544A1 (en) | Tumor immune enhancer, and preparation method therefor and application thereof | |
| JP2002356498A (ja) | 滑膜肉腫抗原ペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS POSTBOKS 765 SENTRUM OSLO, 0106 NO |
|
| MM1K | Lapsed by not paying the annual fees |